Humoral immune response to viral accessory gene products in HIV-1 infection |
|
Increase in carotid artery intima-media thickness and arterial stiffness but improvement in several markers of endothelial function after initiation of antiretroviral therapy |
|
Increased burden of concordant and sequential anogenital human papillomavirus infections among Asian young adult females with perinatally acquired HIV compared to HIV-negative peers |
|
Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase |
|
Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations |
|
Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection |
|
Infection with HIV-1 induces a decrease in mtDNA |
|
The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers |
|
Insulin sensitivity in multiple pathways is differently affected during zidovudine/lamivudine-containing compared with NRTI-sparing combination antiretroviral therapy |
|
An internationally generalizable risk index for mortality after one year of antiretroviral therapy. |
|
Invasive external otitis caused by Aspergillus fumigatus in two patients with AIDS |
|
Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals? |
|
Is the male genital tract really a sanctuary site for HIV? Arguments that it is not. |
|
Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? |
|
Lack of activity of zidovudine in AIDS-associated Kaposiʼs sarcoma |
|
Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. |
|
[LAV/HTLV-III infection after a one-time sexual contact with an AIDS patient] |
|
Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals |
|
Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways |
|
Liver decompensation in HIV/Hepatitis B coinfection in the cART era does not seem increased compared to hepatitis B mono-infection |
|
Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study |
|
Long-Term Changes of Subcutaneous Fat Mass in HIV-Infected Children on Antiretroviral Therapy: A Retrospective Analysis of Longitudinal Data from Two Pediatric HIV-Cohorts |
|
Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe. |
|
Long-term exposure to combination antiretroviral therapy and risk of death from specific causes |
|
Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. |
|
Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels: the D:A:D study |
|
The lopinavir/ritonavir-associated rise in lipids is not related to lopinavir or ritonavir plasma concentration |
|
Low antigenicity of HIV-1 rev: rev-specific antibody response of limited value as correlate of rev gene expression and disease progression |
|
Low bone mineral density, regardless of HIV status, in men who have sex with men. |
|
Low mother-to-child-transmission rate of Hepatitis C virus in cART treated HIV-1 infected mothers |
|
Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication |
|
Markedly diminished lipolysis and partial restoration of glucose metabolism, without changes in fat distribution after extended discontinuation of protease inhibitors in severe lipodystrophic human immunodeficient virus-1-infected patients |
|
Mitochondrial DNA assessment in adipocytes and peripheral blood mononuclear cells of HIV-infected patients with lipodystrophy according to a validated case definition |
|
Mitochondrial DNA decline in T cells of HIV-1 seroconverters may be dependent on immune activation |
|
Monocyte and T Cell Immune Phenotypic Profiles Associated With Age Advancement Differ Between People With HIV, Lifestyle-Comparable Controls and Blood Donors |
|
Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study |
|
Multivariate normative comparison, a novel method for more reliably detecting cognitive impairment in HIV infection |
|
Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort |
|
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1 |
|
Nevirapine plus didanosine: once or twice daily combination? |
|
No evidence for accelerated ageing-related brain pathology in treated HIV: longitudinal neuroimaging results from the Comorbidity in Relation to AIDS |
|
Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study |
|
Noncommunicable Diseases in People Living With HIV: Time for Integrated Care. |
|
O313 Relation between adverse effects of ARV treatment and underlying risk in number needed to treat to harm |
|
O314 Predicting the short-term risk of diabetes in HIV-infected patients in the D:A:D cohort: the D:A:D study group |
|
Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons |
|
[A patient with a mild form of the acquired immunodeficiency syndrome |
|
Patients' Willingness to Take Multiple-Tablet Antiretroviral Therapy Regimens for Treatment of HIV |
|
Patterns of co-occurring comorbidities in people living with HIV |
|
Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents |
|
Perceptions of HIV cure and willingness to participate in HIV cure-related trials among people enrolled in the Netherlands cohort study on acute HIV infection |
|
Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular rather than glomerular toxicity. |
|
Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. |
|
Poorer cognitive performance in perinatally HIV-infected children versus healthy socioeconomically matched controls |
|
Predicting Virological Response to HIV Treatment Over Time: A Tool for Settings With Different Definitions of Virological Response |
|
Predictive Performance of Cardiovascular Disease Risk Prediction Algorithms in People Living With HIV |
|
Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta-analysis |
|
Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals |
|
Predictors of hypertension and changes of blood pressure in HIV-infected patients. |
|
Predictors of Ischemic and Hemorrhagic Strokes Among People Living With HIV: The D:A:D International Prospective Multicohort Study |
|
Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study |
|
Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients |
|
Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression |
|
Relations among CD4 Lymphocyte Count Nadir, Antiretroviral Therapy, and HIV-1 Disease Progression: Results from the EuroSIDA Study |
|
Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. |
|
Results of long-term follow-up of HIV-infected patients treated with lamivudine monotherapy, followed by a combination of lamivudine and zidovudine |
|
Resumption of HIV antigen production during continuous zidovudine treatment |
|
Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy |
|
Ritonavir protects against the development of atherosclerosis in APOE*3-Leiden mice |
|
Safe Interruption of Maintenance Therapy against Previous Infection with Four Common HIV-Associated Opportunistic Pathogens during Potent Antiretroviral Therapy |
|
Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe |
|
Seroconversion to HIV-1 negative regulation factor |
|
Sleutel tot succes |
|
Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America |
|
Sources of HIV infection among men having sex with men and implications for prevention |
|
Telomere Length, Traditional Risk Factors, HIV-related Factors and Coronary Artery Disease Events in Swiss Persons Living with HIV |
|
Temporary increase in serum beta 2-microglobulin during treatment with interferon-alpha for AIDS-associated Kaposi's sarcoma |
|
Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals |
|
Trends in underlying causes of death in people with HIV from 1999 to 2011 |
|
An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype |
|
Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons |
|
Use of competitive polymerase chain reaction to determine HIV-1 levels in response to antiviral treatments |
|
Viral replication under combination antiretroviral therapy: a comparison of four different regimens. |
|
Virological and Social Outcomes of HIV-Infected Adolescents and Young Adults in The Netherlands Before and After Transition to Adult Care |
|